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Systemic diseasea b s t r a c t
This is a Brighton Collaboration Case Definition of the term ‘‘Vaccine Associated Enhanced Disease” to be
utilized in the evaluation of adverse events following immunization. The Case Definition was developed
by a group of experts convened by the Coalition for Epidemic Preparedness Innovations (CEPI) in the con-
text of active development of vaccines for SARS-CoV-2 vaccines and other emerging pathogens. The case
definition format of the Brighton Collaboration was followed to develop a consensus definition and
defined levels of certainty, after an exhaustive review of the literature and expert consultation. The doc-
ument underwent peer review by the Brighton Collaboration Network and by selected Expert Reviewers
prior to submission.
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Vaccine-associated enhanced diseases (VAED) are modified pre-
sentations of clinical infections affecting individuals exposed to a
wild-type pathogen after having received a prior vaccination for
the same pathogen [1]. Vaccine-associated enhanced respiratory
(VAERD) disease refers to disease with predominant involvement
of the lower respiratory tract. Classic examples of VAED are atypi-
cal measles and enhanced respiratory syncytial virus (RSV) occur-
ring after administration of inactivated vaccine for these
pathogens. In this situation, severe disease has been documented
resulting from infection in individuals primed with non-
protective immune responses against the respective wild-type
viruses [2–6]. Given that these enhanced responses are triggered
by failed attempts to control the infecting virus, VAED typically
presents with symptoms related to the target organ of the infection
pathogen. In order to recognize vaccine associated disease
enhancement, it is therefore necessary to have a clear understand-
ing of the clinical presentation and usual course of the natural
disease.
Disease enhancement independent of vaccine priming has also
been described for pathogens causing sequential infections with
different cross-reactive but not cross-protective serotypes, includ-
ing dengue and pandemic influenza [7–12].
In late 2019, a novel severe respiratory illness emerged in
Wuhan, China [13]. The causative agent, Severe Acute Respiratory
Syndrome Coronavirus-2 (SARS-CoV-2), was promptly identified,
and determined to be closely related to SARS and the Middle East
Respiratory Syndrome (MERS) coronaviruses, which had caused
geographically localized outbreaks in 2002–2004 and from 2012
onwards, respectively. SARS-CoV-2 progressed to a global pan-
demic with substantial consequences due to its high infectivity
and transmissibility, and its ability to cause both a severe respira-
tory illness, and a systemic disease with fatal consequences for vul-2
nerable populations. The natural history of coronavirus infectious
disease caused by SARS-CoV-2 (COVID-19), is yet to be fully
described. However, a case fatality rate that ranges from 0.5% to
nearly 20% depending on age and other risk factors, and the under-
standing that SARS-CoV-2 is now a well-adapted human pathogen
that will continue to cause disease in susceptible populations,
makes the development of an effective vaccine a global priority.
The potential for vaccination against SARS-CoV-2 to be associ-
ated with disease enhancement is of theoretical concern, given
similar observations with other respiratory viruses in general,
and in animal models of highly pathogenic coronaviruses in partic-
ular [14]. Importantly, VAED has not been seen following SARS or
MERS vaccines given to humans, albeit the number of people
who received these experimental vaccines remains very small. At
this time, the pathogenesis, host responses and immunity to
SARS-CoV-2 are still being evaluated and are not fully understood.
SARS-CoV-2 infection is associated with a spectrum of disease that
varies from asymptomatic infection to severe lung disease with
acute respiratory distress syndrome (ARDS) and a fatal multiorgan
disease with inflammatory, cardiovascular, hematologic and coag-
ulation dysregulation [15–17]. Post-infectious, possibly immune-
mediated systemic disease has also been described, particularly
the multisystemic inflammatory syndrome in children (MIS-C)
and adults (MIS-A) of unclear pathogenesis at this time [18–21].
Given the broad spectrum of disease associated with SARS-CoV-
2, clinical assessment of both systemic VAED and lung-specific
VAERD will be challenging during the pre-licensure evaluation of
candidate vaccines and after the implementation of widespread
vaccination for COVID-19. The broad spectrum of natural disease
manifestations in different populations and age groups makes it
very difficult, if not impossible, to determine how severe COVID-
19 infection would have been in the absence of vaccination in the
individual case. Someone who might have been completely asymp-
tomatic without prior vaccination but who develops mild respira-
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be considered a case of VAERD. However, this end of the spectrum
of possible VAERD would have very little clinical significance for
this individual person. At the population level however, even a
small shift in the spectrum of disease towards greater severity
could have major clinical and societal impact. Furthermore, given
that severe illness is more feasible to detect and characterize, the
case definitions discussed herein focus on the more severe presen-
tations of VAED/VAERD.
There is no uniformly accepted definition of VAED or VAERD.
Frequently used related terms include ‘‘vaccine-mediated
enhanced disease (VMED)”, ‘‘enhanced respiratory disease (ERD)”,
‘‘vaccine-induced enhancement of infection”, ‘‘disease enhance-
ment”, ‘‘immune enhancement”, and ‘‘antibody-dependent
enhancement (ADE)”. This is potentially confusing as the mecha-
nisms for disease enhancement likely vary, and data comparability
across trials or surveillance systems can be problematic when the
systems do not utilize a consistent case definition and do not col-
lect comparable data. However, the assessment of this potential
adverse event following immunization is particularly important
for SARS-CoV-2, given the urgent global need for safe and effective
vaccines. While this case definition was developed for the identifi-
cation of potential cases of VAED/VAERD in the context of SARS-
CoV-2 vaccine development, it is not exclusive for COVID-19 vacci-
nes and may be applied in the evaluation of possible VAED/VAERD
after any vaccine.
1.1. Methods for the development of the case definition
The Brighton Collaboration VAED working group was formed in
March 2020 and included members with expertise in basic science,
virology, animal models, immunology, vaccinology, vaccine safety,
clinical care, clinical research, public health, regulatory sciences
and ethics.
To guide the decision-making for the case definition and guide-
lines, a series of literature searches were performed using PubMed.
The search terms and results of the searches are described in detail
in Appendix A.
To address the current state of knowledge and knowledge gaps
for the assessment of VAED in the context of the assessment of vac-
cines for SARS-CoV-2, a Consensus Conference of Experts, including
the authors of this case definition, was convened on March 12–13,
2020. The topics of discussion and conclusions of this meeting are
published [22]. The group of experts in this Consensus Meeting
concluded that the demonstration of some disease enhancement
with any candidate vaccine after viral challenge in animal models
should not necessarily represent a ‘‘no-go” signal for deciding
whether to progress into early trials in clinical development of a
COVID-19 vaccine. However, continuous monitoring of this risk
during clinical trials in an epidemic context will be needed. Each
observed effect should be discussed by the vaccine developers with
the respective regulatory agencies who will ultimately define the
actual requirements for clinical studies.
The working group determined that describing the known
pathophysiologic pathways leading to VAED/VAERD was necessary
to highlight the different potential mechanisms of disease, because
an established clinical, laboratory or histopathologic definition of
VAED or VAERD is not available. The case definition focuses on
the identification of possible and probable cases of VAED/VAERD
after any vaccination based on clinical presentation and frequency
of clinical outcomes of concern, and provides suggested clinical
and laboratory evaluation tools. However, while describing options
for evaluation of possible cases when planning clinical trials or
safety surveillance, a specific biomarker or histopathologic finding
of VAED does not exist, and therefore, the case definition is not pre-
scriptive regarding the specific tests to perform, nor when and who3
should be conducting or interpreting such testing. Furthermore,
with the current state of knowledge, the ‘‘gold standard” evalua-
tion to diagnose a definitive case of VAED/VAERD may be
pathogen- and vaccine-specific and cannot be defined until more
clinical and research data become available, in consultation with
experts.
1.2. Defining pathophysiologic pathways leading to VAED/VAERD
Previous experiences of specific vaccine enhanced diseases
serve as examples of how various pathophysiologic mechanisms
can lead to VAED or VAERD. The mechanisms are outlined below.
1.2.1. Immune complex mediated enhanced disease (RSV, measles,
pandemic influenza)
Shortly after the successful inactivation of polioviruses with
formaldehyde, and the success of that vaccine for the control of
epidemic polio, other pediatric pathogens were targeted for vac-
cine development using similar methods. In the mid-1960s, a
formalin-inactivated vaccine against RSV was administered to
infants and young children in four studies in the United States
[23–26]. Children were subsequently exposed to wild-type virus
in the community, and those immunized children who were
seronegative for RSV before vaccination experienced an enhanced
and atypical presentation of RSV disease, with fever, wheezing,
and bronchopneumonia. These children were more frequently hos-
pitalized and two children vaccinated in infancy, died as a conse-
quence of the RSV infection [23]. In contrast, enhanced
respiratory disease (ERD) was not observed in infants who were
seropositive for the virus at the time of administration of the
formalin-inactivated RSV vaccine [23].
The potential reason for the enhanced disease associated with
the formalin-inactivated vaccine was that a non-protective anti-
body response of low affinity for the RSV fusion (F) protective anti-
gen was generated [27–29]. This low-avidity, non-protective
response elicited by formalin-inactivated vaccines has been linked
to deficient Toll-like receptor (TLR) activation at the time of immu-
nization [27–31]. Subsequent RSV infection leads to immune com-
plex formation and complement activation with pulmonary injury,
exacerbation of bronchopneumonia with a Th2 biased CD4 T-cell
response (a distinctive phenotype of the disease) [32–36] and
abundant mucus production [37–38]. Another potential contribut-
ing factor to non-protective antibody responses elicited by
formalin-inactivated vaccine may have been the administration
of RSV F in its post-fusion conformation, which is less stable and
results in antibodies with lower neutralizing capacity than the
pre-fusion conformation [30].
Interestingly, affinity maturation during an earlier exposure to
RSV explains why children who were seropositive for the virus
before inoculation never developed ERD. Preexisting acquisition
of high-avidity antibodies against wild-type RSV likely outcom-
peted low-affinity B cell clones elicited by the formalin-
inactivated RSV vaccine thus eliminating the low affinity non-
protective B cells. This same paradigm explains why no children
experienced ERD twice. After experiencing RSV disease enhance-
ment post-wild-type infection, new antibodies with high affinity
for the virus in these individuals established a healthy response
against subsequent reinfections.
A formalin-inactivated vaccine against measles virus was
licensed in the United States in 1963 simultaneously with the first
live-attenuated measles vaccine [39–40]. Although most people
were initially protected by the formalin-inactivated vaccine, the
relatively low-avidity antibodies elicited by this vaccine failed to
protect at lower titers and led to a severe form of illness known
as atypical measles, in immunized individuals exposed to wild-
type virus [41]. Children with atypical measles presented with high
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[42]. In this case, low-avidity antibodies elicited by the vaccine
failed to neutralize virus that bound to the CD150 high-affinity
receptor in exposed individuals, and promoted immune complex-
mediated illness at sites of measles virus infection, mainly the skin
and lungs [43–46]. Importantly, atypical measles occurred many
years after exposure to the formalin-inactivated vaccine.
After observing the first cases of atypical measles, formalin-
inactivated vaccine recipients not yet exposed to wild-type
measles were inoculated with the licensed live-attenuated vaccine,
with the intent of generating protective antibodies to prevent fur-
ther atypical cases. These individuals developed an erythematous
nodule at the subcutaneous injection site, characterized
histopathologically by measles virus-specific immune complexes
[47–48]. Some failed to mount a corrective immune response fol-
lowing the live-attenuated vaccination, presumably due to neutral-
ization of the vaccine-strain virus by pre-existing antibodies. In
most however, the live attenuated vaccine successfully induced a
high affinity IgG response that could outcompete the potentially
pathogenic antibodies and provide long-term protection.
1.2.2. Cellular immunity in enhanced respiratory disease and atypical
measles.
Atypical measles and ERD are also characterized by a Th2 polar-
ization of their immune response. Although mice are not an ideal
small animal model for either RSV or measles virus infection, an
early evaluation of ERD pathogenesis by Graham et al., showed
increased production of interleukin 4 (IL-4) in lungs of affected
BALB/c mice [35]. Subsequent depletion of CD4+ T lymphocytes
and co-depletion of IL-4 and IL-10 ameliorated ERD lung pathology,
suggesting that the disease was due, at least in part, to an exacer-
bated Th2 response [29,36]. These findings were expanded by
reports of high levels of IL-5 and IL-13, increased numbers of eosi-
nophils, and CD4+ T lymphocytes in mice with ERD [32–33]. In
recent years, a critical role for Th2 bias has been described for
enhanced disease components, including airway hyperreactivity
and mucus hypersecretion [32–33]. Formaldehyde inactivation of
RSV may also have contributed to Th2 polarization during ERD
by generating carbonyl groups on viral antigens [48].
In addition, other T lymphocyte populations may have con-
tributed to ERD pathogenesis and its phenotype. Marked suppres-
sion of T regulatory cells (T-reg) may have exacerbated the Th2
bias in formalin-inactivated RSV vaccine recipients; [49] absence
of RSV-specific cytotoxic T lymphocytes response after immuniza-
tion was permissive for viral replication in the lungs and con-
tributed to a Th2 bias in the anamnestic CD4+ T lymphocyte
response during wild-type infection; [50–51] and eosinophils,
though probably not a critical factor in disease pathogenesis [52],
may be a useful biomarker of undesirable responses in animal
models of disease.
1.2.3. Antibody-mediated enhanced disease (Dengue)
Dengue viruses (DENV) belong to the genus Flavivirus, with four
serologically and genetically distinct serotypes, which differ by 30–
35% amino acid identity. The symptoms of dengue infections range
from asymptomatic in about two-thirds to mild flu-like symptoms
to dengue fever. Dengue hemorrhagic fever/dengue shock syn-
drome is the most severe form of dengue disease and is character-
ized by vascular leakage, hemorrhagic manifestations,
thrombocytopenia, and hypotensive shock. People exposed to their
first DENV infection develop memory B cells and long-lived plasma
cells that produce antibodies that can either be cross-reactive or
specific to the serotype of infection. Secondary DENV infections
induce cross-neutralizing antibodies and protective immunity.
However, priming with one DENV serotype can sometimes
increase the risk of severe dengue upon secondary infection with4
a different DENV serotype. The mechanism for increased disease
severity is thought to be associated with antibody-dependent
enhancement (ADE) [53–54]. It has been postulated that low levels
of antibodies or non-neutralizing antibodies induced by a previous
DENV infection bind to the new serotype of DENV and facilitate
viral entry into Fcc receptor (FccR)-bearing cells, leading to higher
viremia and immune activation. Strong evidence for this ADE
mechanism after natural infection comes from a pediatric cohort
study in Nicaragua, where an increased risk for viremia and severe
disease (7.64-fold higher, 95% confidence interval (CI): 2.19–18.28)
was observed in children with preexisting DENV- antibody levels
of 1:21–1:80 compared to DENV-naïve or those with high
(>1:1280) antibody titers [55].
There is concern that dengue vaccines can induce similar ADE. If
a vaccine produces antibodies with poor neutralizing activity that
bind heterotypic virions without achieving neutralization, the
opsonized viral particle may have an increased ability to infect
Fcc-R-bearing cells (i.e., facilitated entry). If a vaccine does not
induce enough neutralizing antibodies against one or more sero-
types, VAED may develop upon exposure to these serotypes. In a
phase 3 clinical trial, children who received vaccine (DengvaxiaTM:
Sanofi Pasteur) had an increased risk of hospitalization due to den-
gue compared to the placebo group in year 3 after vaccination
[9,56]. While the mechanism of ADE is not proven, prior exposure
to dengue (positive serostatus) is thought to play a critical role, and
those that are dengue-naïve seem to have higher risk of severe dis-
ease after vaccination when subsequently infected with another
serotype of dengue virus [57]. Nevertheless, the data for ADE are
controversial as most of the evidence is anecdotal or based on ani-
mal models.
In in vitro and animal models, a peak enhancement titer (i.e., a
specific concentration of antibodies that most efficiently enhances
DENV infection) has been observed. By contrast, higher antibody
concentrations effectively neutralize virions, whereas lower con-
centrations can enhance infection. However, neutralizing assays
vary from laboratory to laboratory and standardization of such
bioassays across laboratories can be challenging. ADE is also postu-
lated for other arboviruses including Zika and Japanese Encephali-
tis Virus [58–60].
1.2.4. Cytokine activation/storm and enhanced disease (SARS, MERS,
SARS-CoV-2)
Exuberant cytokine activation is considered an important com-
ponent in severe disease caused by SARS-CoV, MERS-CoV or SARS-
CoV-2. The precise mechanism of this immunopathologic response
still remains unclear, since active cytokine/chemokine production
may be an appropriate response to uncontrolled virus replication
as opposed to a truly excessive response. In any case, prolonged
cytokine responses in patients with SARS, characterized by expres-
sion of mainly INF-gamma [61–62], are correlated with worse out-
comes. In these patients, lymphopenia was commonly observed,
which likely reflected effects of elevated levels of cytokines and
endogenous corticosteroids. In one study, prolonged levels of type
I interferon (INF) and other cytokines were observed in SARS
patients who did poorly, while these levels were generally lower
in patients who had better clinical responses, coincident with the
development of protective antibody responses [63]. However, in
other studies, antibody responses were higher in patients with
worse outcomes, raising the possibility that the antibody response
actually contributed to more severe disease. Macrophages are con-
sidered an important source of pro-inflammatory cytokines, but
these cells are not productively infected with SARS-CoV [64–65].
Both macrophages and dendritic cells are abortively infected with
SARS-CoV. While the cells do not support productive infection, in
acute respiratory distress syndrome (ARDS) they were shown to
produce pro-inflammatory cytokines such as TNF, IL-1beta, IL-6,
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excessive cytokine activation in SARS comes from mouse studies.
Mice infected with mouse-adapted SARS-CoV develop a lethal
pneumonia, characterized by rapid virus replication and peak virus
titers within 16–24 h. However, 100% of mice survive if type I IFN
signaling is blocked either by genetic deletion or treatment with
antibody that blocks INF signaling [69].
Similar mechanisms appear to occur in MERS patients, although
less is known because there have been only approximately 2500
cases since MERS was first identified in 2012. As in SARS, MERS
patients tend to have (delayed) elevated levels of pro-
inflammatory cytokines such as IL-1beta, IL-6 and IL-8 [70].
MERS-CoV, unlike SARS-CoV, actively inhibits the induction of an
early IFN-I response, allowing for enhanced virus replication [71].
Also unlike SARS-CoV, MERS-CoV is sensitive to IFN-I therapy
[71]. MERS-CoV was shown to productively infect macrophages
and dendritic cells, with delayed induction of IFN-I and other
cytokines [72]. Thus both SARS-CoV and MERS-CoV induce the
expression of pro-inflammatory molecules, even though their abil-
ity to replicate in myeloid cells differs substantially.
Although SARS-CoV-2 has been in human populations for only a
few months, several studies have suggested that excessive cyto-
kine activation contributes to pathogenesis. Molecules, such as
IL-1, IL-6, TNF, IL-8 are upregulated in patients with more severe
disease, raising the possibility that some of them may contribute
to poor outcomes [73]. IL blocking antibodies are being used clin-
ically in both controlled and uncontrolled clinical trials.
ADE has only been convincingly demonstrated in coronavirus
infections in cats that were previously seropositive from infection
or vaccination and immunized with S protein expressing vectors
followed by challenge with feline infectious peritonitis virus [73].
However, VAERD has occurred after immunization with SARS inac-
tivated vaccines or alphavirus vectors expressing the nucleocapsid
protein. In many instances, inflammatory infiltrates exhibit a Th2
rather than a Th1 phenotype and are characterized by increased
numbers of eosinophils [74–77]. In another study, macaques were
immunized with vaccinia virus expressing the SARS protein or pas-
sively immunized with plasma from macaques immunized with
the same vector. They were then challenged with SARS-CoV. While
the animals remained asymptomatic, the nature of the inflamma-
tory infiltrates changed, most prominently from M2- to M1-type
macrophages, with increased expression of pro-inflammatory
cytokines. Of note, this modification in the immune response did
not result in a change in clinical disease [78].
1.2.5. Vaccine-induced enhancement of acquisition of infection
The first large placebo controlled trial (STEP trial) of an Ad5-HIV
vaccine candidate was terminated early when a planned interim
analysis demonstrated a significantly higher rate of HIV infection
in male vaccinees who had been Ad5 seropositive at baseline vs.
placebo (5.1% versus 2.2% per year) and/or were uncircumcised
(5.2% versus 1.4% per year) [79]. A longer term follow-up analysis
(after unblinding) supported the initial finding of enhanced acqui-
sition of HIV infection in the vaccinees compared to the placebo
group [80]. Although the difference in the rate of HIV infection
was relatively small, it was statistically significant (Hazard ratio
of 1.40 (95% CI, 1.03–1.92; p = 0.03)). In an expanded analysis of
data, 49 of the 914 male vaccine recipients became HIV infected
(annual incidence 4.6%, 95% CI 3.4 to 6.1) and 33 of the 922 male
placebo recipients became HIV infected (annual incidence 3.1%,
95% CI 2.1 to 4.3). Potential explanations of this increased suscep-
tibility to HIV infection in the vaccinees included the lack of an
HIV-Env antigen in the vaccine, with the possibility that the HIV
immune response induced by the vaccine potentially induced
attachment of HIV to cellular surface, but without killing or neu-
tralizing the virus, thus enabling viral entry into the cell. While5
the cause of the apparent vaccine-induced increased susceptibility
to acquisition of HIV infection was never fully explained, the con-
clusion that the vaccine enhanced acquisition of HIV infection
remained firm. The clinical data in those vaccinees who were
infected were also suggestive of disease enhancement, or at least
reduction of the time from acquisition of infection to onset of dis-
ease manifestations.
Although no other vaccine has been definitively linked to
enhanced acquisition of infection, it is likely that this is not an out-
come unique to HIV infection. Enhanced disease associated with
inactivated measles or RSV vaccines has become accepted has hav-
ing occurred, but enhanced acquisition of infection was not widely
reported for either the formalin-inactivated RSV and inactivated
measles vaccines. However, this may not have been noted due to
the high infection rate for measles or RSV in the study populations
at the time. Additionally, the four formalin-inactivated RSV vaccine
trials were not placebo-controlled [23–26]. A control vaccine
(Parainfluenza 3 vaccine candidate – PIV3) or historical controls
were used. Nevertheless, in two of the RSV vaccine trials [23],
the attack rates, particularly in infants less than 12 months of
age, were higher than in the PIV3 control group. In one study, 23
of 31 (74%) of RSV vaccinated infants later developed RSV infection
compared to 21 of 40 (53%) RSV infections in the infants receiving
PIV3 (unadjusted chi-square 5.1505; p-value is 0.023) [23]. In a
second study, 13 of 43 (30%) RSV vaccinated infants later devel-
oped RSV infection compared to 5 of 46 (11%) RSV infections in
the infants receiving PIV3 (unadjusted chi-square 5.1645; p-value
is 0.023) [24].
In the case of the inactivated measles vaccine, the inactivated
measles vaccine was evaluated in trials which compared inacti-
vated vaccine plus at least one dose of live measles vaccine to a live
measles vaccine alone control group [81]. Thus, although enhance-
ment of clinical measles was noted in the inactivated measles vac-
cine group, the number of breakthrough cases of measles was too
small to detect a difference in incidence.
Thus, while the occurrence of enhanced acquisition of HIV
infection, induced by an Ad5-HIV vaccine candidate became gener-
ally acknowledged as a consequence of immunization with that
particular vaccine, enhanced acquisition of infection has not been
perceived as having occurred with other vaccines. Although the
difference in the numbers of HIV infection was relatively small in
the STEP trial, the denominators were large and the conclusion that
the Ad5-HIV vaccine caused enhancement of acquisition is now
generally accepted. For the inactivated RSV vaccine, the trials were
relatively small, but the rates of breakthrough RSV infections were
much higher and also resulted in statistically significant increases
in infection rates in the RSV vaccine groups. This apparent
enhanced acquisition of infection may have been overlooked
because the severity of enhanced disease occurring in the vacci-
nees overshadowed the higher risk of RSV infection associated
with the vaccine and because the background rates of RSV infec-
tion were high in both RSV and PIV3 control vaccines recipients.
1.3. How do existing animal models inform assessment of VAED in
humans?
Although animal models have been developed for most respira-
tory viruses, they rarely reproduce the full spectrum of the corre-
sponding human disease. Therefore, the assessment of the risk of
VAED in animal models is imperfect and limited. However, animal
models can still provide useful information on potential patho-
genic mechanisms and identify markers of potential risks that
can be considered for inclusion in clinical trials.
Some lessons may be retained from the previous VAED experi-
ence. Today, preclinical RSV vaccine studies that indicate the
induction of weak neutralizing and strong non-neutralizing
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VAED may lead to changes in vaccine design strategies. First the
selection of antigen(s) is critical to ensure an appropriate balance
of neutralizing vs non-neutralizing antibody production. Second,
some candidate subunit RSV vaccines are now formulated with
Th1-driving adjuvants, which will diminish a prominent Th2
response and an eosinophilic reaction after exposure to the wild
virus. Third, preference can be given to RSV vaccines that can
induce long-lasting and powerfully neutralizing antibody
responses and affinity maturation in order to avoid a gradual wan-
ing of antibody levels.
When planning phase 1/2 clinical trials of new candidate vacci-
nes against acute respiratory infections, it is useful to analyze
markers of innate and acquired immunity, and observations made
in animal models may be informative. Regarding innate immunity,
a detailed assessment of monocytes and NK-cell phenotypic mark-
ers and various circulating cytokines (e.g. IFN-alpha, IL-10) in the
first 24 h post-immunization has been shown to correlate with
long term features of subsequent antibody responses [82]. T-cell
responses also need to be monitored, including a cytokine profile
analysis of both CD4 and CD8 T-cell responses, with multiple Th1
and Th2 markers. The absence of Th2 markers such as IL-4, IL-5
or IL-13, in the presence of consistent IFN-gamma responses may
indicate a lower risk of some forms of VAED. Animal models have
identified antibody response patterns that are associated with low
risk of VAED including a high ratio of neutralizing vs. antigen-
binding antibodies anti-receptor binding domain (RBD) antibodies
of high affinity (nanomolar range), and antibody kinetics showing
sustained IgG responses over time. One may also consider the pas-
sive transfer of serum (containing different antibody levels) from
immunized Phase 1 trial participants into suitable animal models,
prior to viral challenge, to assess the risk of enhanced disease after
infection.
1.4. Knowledge gaps in current understanding of potential VAED in the
context of SARS-CoV-2
1.4.1. Mechanisms
Various distinct pathways may lead to VAED. SARS-CoV-2 is a
novel pathogen facing no specific immunity in populations of all
ages and it presents a considerable degree of variability in its clin-
ical manifestations. In addition, its mechanisms of pathogenesis
are still unclear. Therefore, understanding how aberrant immune
responses may alter a process that is not yet well characterized
and that itself presents a considerable range of clinical manifesta-
tions is difficult. However, VAED always involves a memory
response primed by vaccination and, in the experiences best char-
acterized until now, targets the same organs as wild-type infec-
tions. The availability of clinical data and samples from patients
with wild-type infections (not vaccinated) is therefore critical to
make any assessments and decisions regarding the presence of dis-
ease enhancement when analyzing a vaccine candidate.
1.4.2. Animal models
There are a few critical details that should be considered when
testing vaccine candidates for the risk of VAED in animal models,
regardless of the species selected: [1] the need for a negative
wild-type infection control group is paramount. A vaccine may
seem safe in the absence of a baseline wild-type infection control,
particularly when the VAED positive control presents an exagger-
ated phenotype; [2] the importance of methodically clearing all
control inoculations and challenges from cellular debris, which
may enhance reactogenicity in animal models and bias observa-
tions; [3] while acknowledging the urgency of the ongoing pan-
demic, it may be important to wait a considerable period of time6
between immunization and challenge, since early challenge might
prevent investigators from seeing effects that would become obvi-
ous later. For this purpose, challenging after antibody titers fall to
low – possibly non-protective - levels may be most informative;
[4] carefully selecting reproducible models of VAED as positive
controls in the evaluation. Some animal models may not exhibit
the same manifestations reproducibly and a negative test in the
absence of proper positive controls may be deceptive; and [5] pri-
oritize models with clinical manifestations of illness over those
exhibiting only pathological changes. Otherwise, results may be
distorted by emphasizing pathological differences of uncertain
clinical relevance.1.4.3. Vaccine platforms
Numerous vaccines are under evaluation for SARS-CoV-2 and
other emerging pathogens [83]. These include well established
vaccine constructs used in existing licensed vaccines (protein sub-
unit, inactivated, virus-like particle, and replicating viral vectored
vaccines), and new technologies (nucleic acid, DNA or mRNA-
based vaccines) that allow for the rapid development of vaccine
candidates [84]. Certain vaccines may be more appropriate for
specific populations, such as the elderly, children and pregnant
women, compared with healthy adults. The safety, immunogenic-
ity and efficacy of SARS-CoV-2 vaccines must be carefully evalu-
ated prior to their use in the general population, particularly
given concerns for disease enhancement and the global need for
effective vaccines to control the COVID-19 pandemic.1.4.4. Adjuvants
Adjuvants have been used in vaccines and given to billions of
individuals. Based on this experience and in the context of vaccine
development against other pandemic viruses responsible for acute
respiratory viral infections, adjuvants may help to: [1] enhance the
level and durability of protective humoral response and broaden its
epitope-related specificity [2] induce skewed response towards
more functional immune responses, including cellular response
and [3] generate antigen-sparing approaches able to deliver more
vaccine doses in the context of an ongoing pandemic.
Adjuvants have the capacity to increase immune responses
through the activation of innate immunity, conditioning the level
and quality of antibodies and T-cell responses specific to the vac-
cine antigen [85]. In addition to antibodies, the most potent adju-
vants such as emulsions or those containing saponins and Toll-like
receptor ligands have been shown to induce robust and long last-
ing polyfunctional CD4 + T-cell responses, with a predominant
IL-2, IFN-g and TNF response, but remarkably little Th2-
associated cytokines [86–87]. CD8 T-cell responses are also gener-
ally not increased by adjuvanted recombinant vaccines.
In the context of disease enhancement, the use of appropriate
adjuvants in subunit vaccines may therefore be a possible avenue
to manage the potential risk of VAED, in particular those that
induce a more potent innate response. However, both pre-
existing immunity and the type of antigen influence the impact
of the adjuvant on the immune response, and therefore each anti-
gen/adjuvant combination needs to be specifically evaluated. The
safety profile of adjuvanted vaccines will also depend on the adju-
vant’s mode of action. In early clinical trials of candidate vaccines,
it will be important to assess the impact of adjuvant not only on
the magnitude, but more critically, on the quality of the immune
response, such as antibody functionality and T-cell profiling. In this
regard, non-human primates rather than mice have been shown to
best reflect the behavior of adjuvants observed in humans and
therefore constitutes a good predictive model for formulation
selection [88].
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No single or combination of specific confirmatory tests is avail-
able to diagnose VAED. As the clinical manifestations of VAED lies
within the spectrum of natural disease – occurring more frequently
and/or severely in vaccinated individuals – it is also difficult to sep-
arate vaccine failure (also called breakthrough disease) from VAED
in vaccinated individuals. All cases of vaccine failure should be
investigated for VAED. Vaccine failure is defined as the occurrence
of the specific vaccine-preventable disease in a person who is
appropriately and fully vaccinated, taking into consideration the
incubation period and the normal delay for the protection to be
acquired as a result of immunization [89]. Assessment of single
or multiorgan dysfunction, atypical immune and inflammatory
responses, viral identification and quantification, and histopathol-
ogy may aid in the diagnosis and classification of the extent and
severity of disease occurring after vaccination. However, definitive
case ascertainment of VAED/VAERD might not be possible, and
ascertainment of occurrence of VAED/VAERD might only be feasi-
ble in the context of large randomized controlled clinical trials or
during post-licensure safety surveillance.
1.6. Disease severity assessment and classification
A classification or a standardized method for the assessment of
disease severity are not available for VAED/VAERD. In the case of
dengue infection, where the occurrence of antibody-mediated dis-
ease enhancement upon reinfection is a well described phe-
nomenon, the existing clinical classification characterizes the
more severe manifestations of disease. Similarly, existing clinical
disease characterizations and severity of illness scores may be uti-
lized to identify and classify cases of severe or enhanced disease
occurring after vaccination.
2. Rationale for selected decisions about the case definition of
vaed/vaerd as an adverse event following immunization
In general, VAED is a modified and/or severe presentation of an
infectious disease affecting individuals exposed to the wild-type
pathogen after having received vaccine designed to prevent
infection.
An accepted case definition of VAED does not yet exist. Simi-
larly, harmonized, specific guidance from regulatory bodies regard-
ing the assessment of clinical trial subjects for VAED, is not yet
available. A consensus definition is necessary not only in the con-
text of vaccine clinical trials to allow for comparability among dif-
ferent vaccines and clinical studies, but also for the assessment of
safety after vaccine licensure and implementation.
2.1. Case definition
2.1.1. Vaccine-associated enhanced disease (VAED)
1. Is an illness that occurs in persons who receive a vaccine and
who are subsequently infected with the pathogen that the vac-
cine is meant to protect against. This definition assumes previ-
ously antigen-naïve vaccine recipients, which can be assessed
by determining seronegative status prior to vaccination, when
feasible. The need for documentation of seronegativity prior
to vaccination, which can be done retrospectively, is particu-
larly relevant in Phase II-III clinical trials. In the context of such
trials, the working group acknowledged the difficulty in distin-
guishing between vaccine failure and VAED. Thus, all cases of
vaccine failure should be evaluated for VAED.7
2. VAED may present as severe disease or modified/unusual clini-
cal manifestations of a known disease presentation. The illness
presumably is more severe or has characteristics that distin-
guish it from illness that might occur in unvaccinated
individuals.
3. VAED may involve one or multiple organ systems.
4. VAED may also present as an increased incidence of disease in
vaccinees compared with controls or known background rates.
2.1.2. Vaccine-associated enhanced respiratory disease (VAERD)
5. Refers to the predominant lower respiratory tract presentation
of VAED. The mechanisms of pathogenesis might be specific to
the lower respiratory tract or part of a systemic process.
2.1.3. Approach for identification of cases of VAED/VAERD
In the context of vaccine clinical trials, the routine collection of
adverse events (AE), serious adverse events (SAE), and adverse
events of special interest (AESI) is an existing mechanism to eval-
uate the occurrence of illnesses and outcomes that are serious,
including those that are new, require medical care, result in dis-
ability, are life threating or result in hospitalization or death. Sim-
ilarly, AEs are evaluated for severity, using existing tools, such as
severity grading scales and toxicity tables for clinical and labora-
tory outcomes that are adapted to various populations including
adults, children and pregnant women [DAIDS Toxicity tables
https://rsc.niaid.nih.gov/sites/default/files/daidsgradingcorrected-
v21.pdf]. The working group concurs that these methods of assess-
ment of events occurring after vaccination are appropriate to
identify triggers that point towards potential cases of VAED/
VAERD. Potential cases may be initially identified though clinical
characteristics alone (Table 1), or complemented with laboratory
evaluation (Table 2).
2.1.4. Identification of VAED/VAERD in clinical trials
Identifying cases of VAED/VAERD might be impossible when
assessing individual patients, however, in clinical studies, a control
group is helpful to compare the frequency of cases and the severity
of illness in vaccinees vs. controls, including the occurrence of
specific events of concern such as hospitalization and mortality.
A comparison group of unvaccinated subjects or active comparator
control group is particularly important when background rates of
the outcome of interest are not available in the target population.
If a control group is not available, comparisons should be made to
the expected background rate of the event of interest when it
occurs after natural disease in an unvaccinated population. When
available, background rates of specific clinical manifestations and
outcomes should be used to compare frequencies. Participation
of an epidemiologist and statistician is recommended in clinical
trial design. Given that the background rate of VAED is unknown,
study sample size calculations in early phases of vaccine evalua-
tion should not be based on the occurrence of VAED/VAERD. How-
ever, in large studies and in post-implementation phases, reliable
surveillance systems should be in place for the timely detection
of potential cases, using estimates of defined specific outcomes
based on expected background rates or control group rates. All
cases of vaccine failure should be evaluated for the possibility of
VAED/VAERD, but not all cases of VAED/VAERD will represent vac-
cine failures. When feasible, a thorough evaluation for alternative
etiologies should be conducted, and an adjudication committee,
or a safety monitoring committee, or independent expert consulta-
tion should be convened to evaluate potential cases.
2.2. Factors to consider in the ascertainment of a case of VAED/VAERD
and levels of Diagnostic certainty are described in Table 3
Table 2
Assessment for VAED in the context of vaccine development: relevant clinical and
laboratory diagnostic parameters.
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In addition to clinical parameters and clinical severity of illness
grading, the diagnosis of VAED/VAERD should be supported by lab-
oratory, radiographic, and pathology findings, as pertinent. A min-
imum set of recommended tests to be applied in the assessment of
a possible case of VAED based on our current knowledge, is
described here and in Table 4.
2.3.1. Viral identification and quantitation
Confirmation of viral infection by detection and quantitation of
virus in specific sites is recommended. These include blood, the
upper and lower respiratory tracts, tissue, and other pertinent ster-
ile sites. Characterization of the virus should be performed when
feasible (e.g., wild-type vs. vaccine virus, sequencing, emergence
of mutations, etc.) Viral quantitation findings should be compared
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d Elevated Ferritin, LDH2.3.2. Immune responses
Evaluation of the immune response after vaccination and at the
time of infection could inform the ascertainment of VAED. When-
ever feasible, the immune responses should be compared to the
expected immune response after natural infection or vaccination.
Assessment of neutralizing and total antibody against specific epi-
topes/targets (for SARS-CoV-2, S and NP) as well as T-cell responses
is recommended. Further studies of antibody neutralization, affin-
ity and other stimulation and proliferation assays could be helpful
to characterize the immune response.Table 1
Factors to consider in the assessment of the clinical presentation of VAED and VAERD.
A  Recognizing VAED in an individual patient is particularly challenging.
VAED might be identified first as a vaccine failure. The clinical presen-
tation may be variable within a spectrum of disease that ranges from
mild to severe, life threatening, with or without long term sequelae,
to fatal.
B  Identification of VAED requires the recognition of a clinical presenta-
tion that is different, atypical, modified or more severe in comparison
to the natural or known (typical) disease presentation, or that occurs
at a higher frequency from the control group or expected background
rates in the specific target population.
 No clinical presentation is pathognomonic for VAED.
C  Identification requires that the clinical syndrome is new or distinct
from the typical presentation or from other known diseases, similar
or associated disorders, or that such clinical syndrome occurs at
higher frequency from the control group or expected background
rates. For example, acute respiratory distress syndrome (ARDS) is a
distinct entity characterized by rapid and progressive inflammatory
changes in the lung parenchyma, resulting in respiratory failure.
Diagnosis is based on clinical characteristics and documentation of
hypoxemia using accepted standardized definitions (eg. Berlin classi-
fication of ARDS). ARDS may occur as a result of a variety of insults
that cause inflammation, alveolar cell injury, surfactant dysfunction,
and other vascular and hematologic abnormalities, including SARS-
CoV-2 infection. ARDS may be a form of clinical presentation of VAED
or VAERD.
D  Assessment of the type and frequency of the clinical presentations by
developing a clinical profile of cases would be helpful to aid in the
more efficient identification of cases through the development of
algorithms [90].
E  Grading of clinical manifestations of disease based on severity using a
standardized and/or validated severity of illness score to evaluate all
cases is recommended. Several tools are utilized in clinical practice
for the assessment of disease severity in adults and children. Com-
monly used and practical scoring tools for adults are shown in Appen-
dix B, and for children in Appendix C. Appropriate tools for the
assessment of severity in various settings (eg. community vs. hospi-
talized cases) should be selected and used consistently [91].
 Whenever feasible, the same clinical scoring tool should be used
across related studies and validated.
d Elevated cytokines
Renal system d Renal dysfunction
d Acute kidney injury
d Renal replacement
therapy
d Decreased urine output
d Serum creatinine
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d Electrolyte abnormalities


























Several characteristics can assist in exploring the potential risk
of VAED in vaccine candidates during early clinical trials. After
immunization, the kinetics of the response (sustained vs. peak-
valley), neutralization titers, the ratio of neutralizing to S-binding
antibodies, and both the absolute affinity for IgG against the RBD
compared to that observed in IgG after wild-type infection and
the progressive acquisition of affinity for RBD over time, may
inform about the quality of antibodies elicited by the immunogens.
After infection, the best information to define the potential for
VAED when exploring antibody-mediated injury is, when possible,
obtaining a biopsy of affected tissues or surrogate materials (e.g.,
from a small skin biopsy in atypical measles to a nasopharyngeal
aspirate in respiratory diseases) that allows detection of C4d depo-
F.M. Munoz, J.P. Cramer, C.L. Dekker et al. Vaccine xxx (xxxx) xxxsition as evidence for complement activation through immune
complex deposition, C1q assessments of immune complexes in flu-
ids, and C3 levels to explore complement consumption. All these
determinations are particularly useful when matched against con-
trol samples from subjects experiencing wild-type disease.
2.3.4. Cell mediated immunity
Cell mediated immunity may be assessed by measurement of
cell counts to determine the presence of lymphopenia or lympho-
cytosis, and quantification of specific cell subtypes, such as CD4
and CD8 T-cells. Functional assays will provide information about
a change from a Th1 to a Th2 CD4 T-cell response. These assays will
measure Th1 (IFN gamma, TNF) vs. Th2 (IL-4, IL-5, IL-13) patterns
of response after in vitro stimulation with viral peptides or pro-
teins, in ELISPOT or intracellular cytokine staining assays.Table 3
Factors to consider in the ascertainment of a case of VAED/VAERD and Levels of Diagnost
Background rates Background rates of specific r
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disease enhancement after na
infection, if the expected initia
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mediated.
Duration of follow up The working group recommen
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c. Worsening or clinical
the anticipated natura
d. Prolonged clinical cou
e. Complications of acu
post-vaccination (for
Control for confounders and comorbidities In the context of evaluating a
drug effects, toxicities, etc. If
including vaccine failure, VAE
Influence of treatment or response to treatment on
fulfilment of case definition
Treatment of VAED and VAER
dysfunction resulting from th
immunomodulatory treatmen
or response to treatment is u
comparative clinical severity
Type of vaccine Vaccines vary based on the an
to determine a priori if any o
working group agrees that it i
given various mechanisms lea
use of convalescent sera or m
mediated mechanisms.
Vaccine enhancement vs. vaccine failure In the event of low/poor vacci
associated with viral replicati
a case where an immune resp
response is induced. A thorou
outcomes is necessary to dist
Geographic and population specific variability in
vaccine responses
Other factors including geogra
status, co-infections, and the
play a role in enhanced disea
9
2.3.5. Serum cytokines and other markers
Cytokines are molecules which are secreted by a multitude of
cells and effect other cells. They are divided into broad categories:
36 different types of interleukins; 17 types of interferons; 48
chemokines, and 17 members of TNF family at the current time,
and more being identified on a regular basis. These cytokines affect
growth, maturation, differentiation, regulation and chemotaxis of
cells. Cytokines may be biomarkers of VAED and part of the mech-
anistic process.
Cytokines can also be used as marker of viral disease process
and worsening infection. For example, in a severe dengue virus
infection, a cytokine storm develops with increased levels of IL-6,
IL-8, IFN-a and IFN-c [92]. Therefore, measuring these cytokines
might indicate a worsening of infection. These cytokines or a sub-
set (IL-6 and IL-8) could also be elevated if a VAED-dependentic Certainty.
elevant conditions and outcomes, including hospitalization and mortality should
grounds rates appropriate to the study population and contemporary to the
used. This information might be unavailable or difficult to obtain. Alternatively,
f events in a control group of unvaccinated individuals is necessary to ascertain
estive of VAED or VAERD. Whenever feasible, it is also important to distinguish
failure (as previously defined).
omes by age group must be described. This is an important factor to consider
presentation from what is expected for a specific age group could be considered
ent, gender differences should be considered.
any time after vaccination. The timing of occurrence of clinical manifestations of
ion will be dependent on the mechanism or pathophysiologic pathway leading to
tural infection. VAED or VAERD may present within 2–4 weeks of natural
l antibody responses are inadequate; or may present at a later time (>1 month or
if antibody waning is noted or if the mechanism is not exclusively antibody
ds that prolonged follow up is established, at least one year after vaccination or
miology of the disease, followed by population-based surveillance in the post-
o taking into consideration what is realistic in the context of a clinical trial, it is
ulation of the target pathogen.In the case of endemic, ongoing active circulation,
re at any time after vaccination, which requires close follow up immediately after
r a prolonged period, depending on the risk of exposure. When pathogens exhibit
re can be identified through seasonal surveillance and may include follow up for a
eferably two, or more seasons, depending on the pathogen. In cases of sporadic
ods may be unknown, and the follow up period may be prolonged.
ld be concerning for VAED or VAERD in a person with confirmed infection:
particularly concerning if death occurs in person without other risk factors for
I-II trials with selected healthy population) or if it occurs at higher rates than
ding hospitalization above expected rates.
deterioration over time, particularly, although not exclusively, if differing from
l course of the disease.
rse compared to natural disease.
te disease, new morbidities or new diagnoses subsequent to natural infection
example higher rate of MIS-C or MIS-A)
case for VAED, it will be important to rule out other infections, comorbidities,
no alternative explanation for the frequency or severity of illness is identified,
D or VAERD may be considered.
D is for the most part, supportive and focused on managing the specific organ
e disease. The use of specific antiviral therapy when available, and of
ts, should be documented. However, the working group considers that treatment
nlikely to be relevant for this case definition as ascertainment is based on
of illness at presentation.
tigen utilized and the addition of adjuvants. At this time, there is insufficient data
f these platforms is less or more likely to be associated with VAED/VAERD. The
s not possible to know the potential risk for VAED/VAERD of an individual vaccine
ding to disease enhancement, and the different affinity for specific receptors. The
onoclonal antibodies might inform potential antibody mediated effect vs. cell
ne efficacy, infection will occur in vaccinated subjects, with breakthrough disease
on. When assessing the safety of a vaccine, there is a need to distinguish between
onse is not induced from a case where an aberrant non-protective immune
gh assessment of immune responses along with protection from serious disease
inguish enhancement from break-through infection.
phic and genetic factors, and individual or population factors such as nutritional
effect of co-administration of medications and non-medical products, might also
se after vaccination.
Table 4
Suggested laboratory evaluation for the assessment of VAED/VAERD.
Parameter Laboratory findings suggestive of
VAED/VAERD
Evidence inadequate or unbalanced
neutralizing antibody responses
 Low or inappropriate total binding
(IgG, IgM, IgA) antibody titers
 Low neutralizing antibody titers
 Low ratio of neutralizing to bind-
ing antibody
 Low absolute affinity of IgG anti-
body to receptor binding domain
(RBD)
 Lack of acquisition or loss of affin-
ity of IgG to RBD
 Increased viral load
Evidence of inadequate or
inappropriately biased cellular
immune responses
 Lymphopenia or lymphocytosis
 High CD4 lymphocyte subset
 Low CD8 lymphocyte subset
 Th2 (IL-4, IL-5, IL-13) CD4 T cell
predominant response over Th1
(INFg, TNF) responses (testing
in vitro stimulation with viral pep-
tides or proteins, ELISPOT, or intra-
cellular cytokine staining assays).




 Elevated IL-1, IL-6, IL-8
 Increased pro-inflammatory
chemo/cytokines: INF-g, type 1-
INF, TNF, CCL2, CCL7
 Reduced expression of type I inter-
ferons (eg. IFN-a, INF-b)
 Elevated C-reactive protein, Fer-
ritin, Lactate dehydrogenase
(LDH), D-dimers
Evidence of immunopathology in
target organs involved, by
histopathology
 Present or elevated tissue eosino-
phils in tissue
 Elevated pro-inflammatory Th2
cytokines in tissue (IL4, IL5, IL10,
IL13)
 C4d tissue deposition (evidence for
complement activation through
immune complex deposition)
 C1q assessments of immune com-
plexes in fluids
 Low C3 levels as evidence comple-
ment consumption
F.M. Munoz, J.P. Cramer, C.L. Dekker et al. Vaccine xxx (xxxx) xxxcytokine storm is developing. In ADE seen after viral infections or
vaccines, decreased antiviral activity with reduced expression of
IFN-a [93] or evidence of worsening virus infection with high titers
or increased pro-inflammatory cytokines may be seen. Skewing to
Th2 cytokines (IL-4, IL-5, IL-13) and associated eosinophilia may
occur as seen in RSV-associated VAED [31]. In the murine model
of RSV, TNF-a and IFN-c are necessary to induce this cytokine
storm as other possible biomarkers [94]. Currently, no cytokine/
chemokine ‘signature’ associated with VAED has been defined
and variability would be expected with different mechanisms of
VAED.
2.3.6. Inflammatory responses
A basic assessment of host immune responses after infection
should include the evaluation of total white blood cell count and
subpopulations (e.g. lymphocyte count, lymphocyte subtypes such
as CD8 or CD4), and measurement of inflammatory markers such
as C-reactive protein (CRP), Ferritin, Lactate dehydrogenase
(LDH), D-dimers, and other specific cytokines (e.g., IL-1, IL-6).
2.3.7. Histopathology (if available)
If available, tissue obtained by biopsy from affected organs or
autopsy should be evaluated for evidence of immunopathology.102.3.8. Radiographic findings
Atypical or more severe involvement of the lower respiratory
tract would be anticipated in patients with VAERD. Chest com-
puted tomography (CT) has a high sensitivity for diagnosis of lower
respiratory tract disease involvement, including for COVID-19 [95–
98]. A standardized reporting system has been proposed for
patients with suspected COVID-19 infection by means of the
‘‘CO-RADS classification”, integrating CT findings with clinical
symptoms and duration of disease (https://radiologyassistant.nl/
chest/covid-19-corads-classification,https://www.rad2share.com/-
covid-19-ct-report-template).3. Case definition of vaccine associated enhanced disease
(VAED)
The case definition of VAED is described in Table 5.
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Table 5
Case definition and Levels of Certainty of Vaccine Associated Enhanced Disease.
LEVEL 1 of Diagnostic Certainty (Definitive case)
The working group considers that a Definitive Case (LOC 1) of VAED cannot be ascertained with current knowledge of the mechanisms of pathogenesis of VAED.
LEVEL 2 of Diagnostic Certainty (Probable)
Rationale for level 2: Ascertainment is based on confirmed infection, with known (2A, higher level of certainty) or without previously known (2B, lower certainty)
serostatus, clinical and epidemiologic criteria, and available histopathology.
LEVEL 2A. A probable case of VAED is defined by the occurrence of disease in a previously seronegative vaccinated individual with:
Laboratory confirmed infection with the pathogen targeted by the vaccine
AND
Clinical findings of disease involving one or more organ systems (a case of VAERD if the lung is the primarily affected organ)
AND
Severe disease as evaluated by a clinical severity index/score (systemic in VAED or specific to the lungs in VAERD)
AND
Increased frequency of severe outcomes (including severe disease, hospitalization and mortality) when compared to a non-vaccinated population (control group or
background rates)
AND
Evidence of immunopathology in target organs involved by histopathology, when available, including any of the following:
 Present or elevated tissue eosinophils in tissue
 Elevated pro-inflammatory Th2 cytokines in tissue (IL4, IL5, IL10, IL13)
 C4d tissue deposition (evidence for complement activation through immune complex deposition)
 C1q assessments of immune complexes in fluids
 Low C3 levels as evidence complement consumptionAND
No identified alternative etiology
LEVEL 2B. A probable case of VAED is defined by the occurrence of disease in a vaccinated individual with no prior history of infection and unknown serostatus, with:
Laboratory confirmed infection with the pathogen targeted by the vaccine
AND
Clinical findings of disease involving one or more organ systems (a case of VAERD if the lung is the primarily affected organ)
AND
Severe disease as evaluated by a clinical severity index/score (systemic in VAED or specific to the lungs in VAERD)
AND
Increased frequency of severe outcomes (including severe disease, hospitalization and mortality) when compared to a non-vaccinated population (control group or
background rates)
AND
Evidence of immunopathology in target organs involved by histopathology, if available, including any of the following:
 Present or elevated tissue eosinophils in tissue
 Elevated pro-inflammatory Th2 cytokines in tissue (IL4, IL5, IL10, IL13)
 C4d tissue deposition (evidence for complement activation through immune complex deposition)
 C1q assessments of immune complexes in fluids
 Low C3 levels as evidence complement consumptionAND
No identified alternative etiology
LEVEL 3 of Diagnostic Certainty (Possible)
Rationale for level 3: Ascertainment is based on confirmed or suspected infection, known (3A higher level of certainty) or unknown (3B lower level of certainty)
serostatus, clinical and epidemiologic criteria, but no histopathology findings.
LEVEL 3A. A possible case of VAED is defined by the occurrence of disease in a previously seronegative vaccinated individual with:
Laboratory confirmed infection with the pathogen targeted by the vaccine
AND
Clinical findings of disease involving one or more organ systems (a case of VAERD if the lung is the primarily affected organ)
AND
Severe disease as evaluated by a clinical severity index/score (systemic in VAED or specific to the lungs in VAERD)
AND
Increased frequency of severe outcomes (including severe disease, hospitalization and mortality) when compared to a non-vaccinated population (control group or
background rates)
AND
No identified alternative etiology
LEVEL 3B. A possible case of VAED is defined by the occurrence of disease in vaccinated individual with no prior history of infection and unknown serostatus, with:
Laboratory confirmed infection with the pathogen targeted by the vaccine
AND
Clinical findings of disease involving one or more organ systems (a case of VAERD if the lung is the primarily affected organ)
AND
Severe disease as evaluated by a clinical severity index/score (systemic in VAED or specific to the lungs in VAERD)
AND
Increased frequency of severe outcomes (including severe disease, hospitalization and mortality) when compared to a non-vaccinated population (control group or
background rates)
AND
No identified alternative etiology
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